Leucine‐rich repeat kinase 2 (LRRK2): A key player in the pathogenesis of Parkinson's disease
Identifieur interne : 000A49 ( Main/Exploration ); précédent : 000A48; suivant : 000A50Leucine‐rich repeat kinase 2 (LRRK2): A key player in the pathogenesis of Parkinson's disease
Auteurs : Payal N. Gandhi [États-Unis] ; Shu G. Chen [États-Unis] ; Amy L. Wilson-Delfosse [États-Unis]Source :
- Journal of Neuroscience Research [ 0360-4012 ] ; 2009-05-01.
English descriptors
- KwdEn :
Abstract
Parkinson's disease (PD) is the most common neurodegenerative movement disorder, with a prevalence of more than 1% after the age of 65 years. Mutations in the gene encoding leucine‐rich repeat kinase‐2 (LRRK2) have recently been linked to autosomal dominant, late‐onset PD that is clinically indistinguishable from typical, idiopathic disease. LRRK2 is a multidomain protein containing several protein interaction motifs as well as dual enzymatic domains of GTPase and protein kinase activities. Disease‐associated mutations are found throughout the multidomain structure of the protein. LRRK2, however, is unique among the PD‐causing genes, because a missense mutation, G2019S, is a frequent determinant of not only familial but also sporadic PD. Thus, LRRK2 has emerged as a promising therapeutic target for combating PD. In this Mini‐Review, we look at the current state of knowledge regarding the domain structure, amino acid substitutions, and potential functional roles of LRRK2. © 2008 Wiley‐Liss, Inc.
Url:
DOI: 10.1002/jnr.21949
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Leucine‐rich repeat kinase 2 (LRRK2): A key player in the pathogenesis of Parkinson's disease</title><author><name sortKey="Gandhi, Payal N" sort="Gandhi, Payal N" uniqKey="Gandhi P" first="Payal N." last="Gandhi">Payal N. Gandhi</name></author><author><name sortKey="Chen, Shu G" sort="Chen, Shu G" uniqKey="Chen S" first="Shu G." last="Chen">Shu G. Chen</name></author><author><name sortKey="Wilson Elfosse, Amy L" sort="Wilson Elfosse, Amy L" uniqKey="Wilson Elfosse A" first="Amy L." last="Wilson-Delfosse">Amy L. Wilson-Delfosse</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:B6D14C4434592FDEC3228C293FB4EF8CE1B37D17</idno><date when="2009" year="2009">2009</date><idno type="doi">10.1002/jnr.21949</idno><idno type="url">https://api.istex.fr/document/B6D14C4434592FDEC3228C293FB4EF8CE1B37D17/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000734</idno><idno type="wicri:Area/Main/Curation">000642</idno><idno type="wicri:Area/Main/Exploration">000A49</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Leucine‐rich repeat kinase 2 (LRRK2): A key player in the pathogenesis of Parkinson's disease</title><author><name sortKey="Gandhi, Payal N" sort="Gandhi, Payal N" uniqKey="Gandhi P" first="Payal N." last="Gandhi">Payal N. Gandhi</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Ohio</region></placeName><wicri:cityArea>Department of Pharmacology, Case Western Reserve University, Cleveland</wicri:cityArea></affiliation></author><author><name sortKey="Chen, Shu G" sort="Chen, Shu G" uniqKey="Chen S" first="Shu G." last="Chen">Shu G. Chen</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Ohio</region></placeName><wicri:cityArea>Department of Pathology, Case Western Reserve University, Cleveland</wicri:cityArea></affiliation><affiliation><wicri:noCountry code="subField">44106‐4965</wicri:noCountry></affiliation></author><author><name sortKey="Wilson Elfosse, Amy L" sort="Wilson Elfosse, Amy L" uniqKey="Wilson Elfosse A" first="Amy L." last="Wilson-Delfosse">Amy L. Wilson-Delfosse</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Ohio</region></placeName><wicri:cityArea>Department of Pharmacology, Case Western Reserve University, Cleveland</wicri:cityArea></affiliation><affiliation><wicri:noCountry code="subField">44106‐4965</wicri:noCountry></affiliation></author></analytic><monogr></monogr><series><title level="j">Journal of Neuroscience Research</title><title level="j" type="abbrev">J. Neurosci. Res.</title><idno type="ISSN">0360-4012</idno><idno type="eISSN">1097-4547</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2009-05-01">2009-05-01</date><biblScope unit="volume">87</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="1283">1283</biblScope><biblScope unit="page" to="1295">1295</biblScope></imprint><idno type="ISSN">0360-4012</idno></series><idno type="istex">B6D14C4434592FDEC3228C293FB4EF8CE1B37D17</idno><idno type="DOI">10.1002/jnr.21949</idno><idno type="ArticleID">JNR21949</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0360-4012</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>leucine‐rich repeat kinase 2 (LRRK2)</term><term>neurodegeneration</term><term>signal transduction</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Parkinson's disease (PD) is the most common neurodegenerative movement disorder, with a prevalence of more than 1% after the age of 65 years. Mutations in the gene encoding leucine‐rich repeat kinase‐2 (LRRK2) have recently been linked to autosomal dominant, late‐onset PD that is clinically indistinguishable from typical, idiopathic disease. LRRK2 is a multidomain protein containing several protein interaction motifs as well as dual enzymatic domains of GTPase and protein kinase activities. Disease‐associated mutations are found throughout the multidomain structure of the protein. LRRK2, however, is unique among the PD‐causing genes, because a missense mutation, G2019S, is a frequent determinant of not only familial but also sporadic PD. Thus, LRRK2 has emerged as a promising therapeutic target for combating PD. In this Mini‐Review, we look at the current state of knowledge regarding the domain structure, amino acid substitutions, and potential functional roles of LRRK2. © 2008 Wiley‐Liss, Inc.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Ohio</li></region></list><tree><country name="États-Unis"><region name="Ohio"><name sortKey="Gandhi, Payal N" sort="Gandhi, Payal N" uniqKey="Gandhi P" first="Payal N." last="Gandhi">Payal N. Gandhi</name></region><name sortKey="Chen, Shu G" sort="Chen, Shu G" uniqKey="Chen S" first="Shu G." last="Chen">Shu G. Chen</name><name sortKey="Wilson Elfosse, Amy L" sort="Wilson Elfosse, Amy L" uniqKey="Wilson Elfosse A" first="Amy L." last="Wilson-Delfosse">Amy L. Wilson-Delfosse</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A49 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000A49 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:B6D14C4434592FDEC3228C293FB4EF8CE1B37D17
|texte= Leucine‐rich repeat kinase 2 (LRRK2): A key player in the pathogenesis of Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |